.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech want to note on the Nasdaq under the symbolic representation “BIOA,” according to records filed with the Stocks as well as Swap Percentage. The provider has not publicly discussed an expected financial amount for the offering.The clinical-stage company proclaims lead candidate azelaprag, a by mouth provided tiny molecule slated to get into period 2 screening in combo along with semaglutide– offered through Novo Nordisk under brand Wegovy for weight-loss– in the first one-half of upcoming year. Semaglutide is actually likewise sold as Ozempic as well as Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is designed to mix effectively along with GLP-1 drugs, enhancing weight management while preserving muscle mass. The investigational drug was actually found to be well-tolerated among 265 individuals across eight period 1 tests, according to BioAge.Previously, BioAge got the support of Lilly to operate a trial integrating azelaprag with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes mellitus as Mounjaro as well as Zepbound for fat burning. The partners are currently administering a phase 2 trial of azelaprag and tirzepatide, along with topline end results anticipated in the third quarter of 2025.The biotech is actually likewise intending a the hormone insulin sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the very first half of following year to assist prospective sign expansion.
Moreover, the business prepares to talk to the FDA for permission in the second half of 2025 to launch individual testing for an NLRP3 prevention targeting metabolic health conditions and also neuroinflammation.BioAge’s anticipated transfer to the public market follows a small uptick in considered biotech IPOs from Bicara Therapeutics as well as Zenas Biopharma. Zooming out, the recent IPO landscape is actually a “blended picture,” along with top quality business still debuting on the public markets, simply in lessened varieties, depending on to PitchBook.